Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-cash Items: 2019-2025

Historic Non-cash Items for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $43.3 million.

  • Fulcrum Therapeutics' Non-cash Items rose 3239.76% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year increase of 3239.76%. This contributed to the annual value of $4.3 million for FY2024, which is 34.87% up from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Non-cash Items is $43.3 million, which was up 95.30% from $22.2 million recorded in Q2 2025.
  • Over the past 5 years, Fulcrum Therapeutics' Non-cash Items peaked at $67.3 million during Q1 2022, and registered a low of $3,971 during Q2 2022.
  • Its 3-year average for Non-cash Items is $10.0 million, with a median of $4.3 million in 2024.
  • Its Non-cash Items has fluctuated over the past 5 years, first tumbled by 99.90% in 2022, then skyrocketed by 16,641.65% in 2023.
  • Fulcrum Therapeutics' Non-cash Items (Quarterly) stood at $1.5 million in 2021, then grew by 27.66% to $1.9 million in 2022, then surged by 701.74% to $15.1 million in 2023, then plummeted by 71.22% to $4.3 million in 2024, then spiked by 3,239.76% to $43.3 million in 2025.
  • Its last three reported values are $43.3 million in Q3 2025, $22.2 million for Q2 2025, and $150,489 during Q1 2025.